Evolent Health, Inc (NYSE:EVH) released its earnings results on Monday. The technology company reported ($0.13) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.13), Briefing.com reports. Evolent Health had a negative net margin of 17.69% and a negative return on equity of 7.06%. The business had revenue of $107.30 million during the quarter, compared to analysts’ expectations of $104.45 million. During the same quarter last year, the company earned ($0.20) earnings per share. The firm’s revenue was up 89.9% on a year-over-year basis.

Shares of Evolent Health (EVH) traded down 0.62% on Monday, reaching $23.95. 1,076,829 shares of the company’s stock were exchanged. The firm’s 50-day moving average price is $25.82 and its 200 day moving average price is $22.62. The company’s market cap is $1.38 billion. Evolent Health has a 12 month low of $14.50 and a 12 month high of $27.50.

In other news, insider Tpg Growth Ii Advisors, Inc. sold 4,279,325 shares of the company’s stock in a transaction that occurred on Wednesday, June 28th. The shares were sold at an average price of $25.87, for a total transaction of $110,706,137.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Cheryl Scott sold 5,477 shares of the company’s stock in a transaction that occurred on Friday, May 19th. The stock was sold at an average price of $23.51, for a total transaction of $128,764.27. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 10,174,238 shares of company stock valued at $254,153,952. 8.79% of the stock is currently owned by insiders.

Several equities research analysts recently weighed in on EVH shares. BidaskClub cut shares of Evolent Health from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, July 25th. Zacks Investment Research upgraded shares of Evolent Health from a “hold” rating to a “buy” rating and set a $26.00 target price for the company in a research note on Wednesday, May 3rd. Jefferies Group LLC reiterated a “buy” rating and issued a $28.00 target price on shares of Evolent Health in a research note on Thursday, April 13th. TheStreet upgraded shares of Evolent Health from a “d” rating to a “c-” rating in a research note on Monday, May 22nd. Finally, Cowen and Company reiterated an “outperform” rating and issued a $35.00 target price on shares of Evolent Health in a research note on Wednesday, June 28th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $30.10.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of US & international copyright & trademark legislation. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/08/07/evolent-health-inc-evh-posts-quarterly-earnings-results-hits-expectations.html.

Evolent Health Company Profile

Evolent Health, Inc is engaged in healthcare delivery and payment. The Company supports health systems and physician organizations in their migration toward value-based care and population health management. The Company provides an end-to-end, technology-enabled services platform for providers. The Company’s platform, powered by its technology, processes and integrated services, enables providers to migrate their economic orientation from fee-for-service (FFS) reimbursement to payment models that reward value-based payment models.

Earnings History for Evolent Health (NYSE:EVH)

Receive News & Ratings for Evolent Health Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health Inc and related companies with MarketBeat.com's FREE daily email newsletter.